TLPH vs. CELU, GNLX, RLYB, LTRN, SNGX, RMTI, MURA, LPTX, THTX, and ANEB
Should you be buying Talphera stock or one of its competitors? The main competitors of Talphera include Celularity (CELU), Genelux (GNLX), Rallybio (RLYB), Lantern Pharma (LTRN), Soligenix (SNGX), Rockwell Medical (RMTI), Mural Oncology (MURA), Leap Therapeutics (LPTX), Theratechnologies (THTX), and Anebulo Pharmaceuticals (ANEB). These companies are all part of the "pharmaceutical preparations" industry.
Celularity (NASDAQ:CELU) and Talphera (NASDAQ:TLPH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, community ranking and risk.
In the previous week, Talphera's average media sentiment score of 0.00 equaled Celularity'saverage media sentiment score.
Celularity has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500. Comparatively, Talphera has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500.
19.0% of Celularity shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 20.7% of Celularity shares are owned by company insiders. Comparatively, 3.0% of Talphera shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Talphera has a consensus target price of $4.50, suggesting a potential upside of 363.73%. Given Celularity's higher possible upside, analysts plainly believe Talphera is more favorable than Celularity.
Celularity has higher revenue and earnings than Talphera.
Celularity received 4 more outperform votes than Talphera when rated by MarketBeat users. However, 100.00% of users gave Talphera an outperform vote while only 42.11% of users gave Celularity an outperform vote.
Talphera has a net margin of 0.00% compared to Talphera's net margin of -1,226.72%. Talphera's return on equity of 30.79% beat Celularity's return on equity.
Summary
Celularity beats Talphera on 7 of the 13 factors compared between the two stocks.
Get Talphera News Delivered to You Automatically
Sign up to receive the latest news and ratings for TLPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TLPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Talphera Competitors List
Related Companies and Tools
